Journal of Drug Delivery Science and Technology最新文献

{"title":"Ligand-functionalized core–shell nanoparticles for precision therapy of luminal A breast cancer: Emerging strategies, clinical challenges, and future perspectives","authors":"Salma Mohamed Ali ,&nbsp;Rehab Galal Abbas Mohamed ,&nbsp;Zahid Hussain","doi":"10.1016/j.jddst.2026.108112","DOIUrl":"10.1016/j.jddst.2026.108112","url":null,"abstract":"<div><div>Luminal A breast cancer, the most common molecular subtype, is typically defined by estrogen receptor (ER) and progesterone receptor (PR) positivity, HER2 negativity, and a low Ki-67 proliferation index, conferring relatively favorable prognosis compared to other breast cancer subtypes. Despite the benefits of endocrine therapy, treatment resistance and recurrence remain major challenges, highlighting the need for more precise drug delivery strategies. Core–shell nanoparticles (NPs) have emerged as versatile platforms that integrate distinct material layers for controlled drug release, enhanced stability, and multifunctional therapeutic applications. Ligand functionalization, particularly with folic acid (FA), hyaluronic acid (HA), peptides, aptamers, and monoclonal antibodies, enables selective targeting of overexpressed receptors on luminal A tumors, thereby improving uptake and therapeutic efficacy. Importantly, recent advances have explored dual-targeting designs that combine ligand functionalization with stimuli-responsive mechanisms (e.g., pH, redox, or enzyme triggers), offering synergistic control over spatial and temporal drug release. Preclinical studies demonstrate significant tumor suppression, survival benefit, and reduced systemic toxicity across multiple in vivo models; however, translation into clinical practice remains constrained by manufacturing complexity, stability issues, and limited validation beyond MCF-7 models. This review uniquely focuses on luminal A breast cancer, distinguishing it from broader breast cancer nanomedicine reports, by emphasizing ligand-functionalized and multi-stimuli-responsive core–shell nanocarriers tailored for this subtype. Looking forward, integration of artificial intelligence–driven design, patient-specific receptor profiling, and scalable manufacturing approaches could accelerate the translation of these nanocarriers into safe and effective therapies for luminal A breast cancer.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108112"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in research methods for the mechanisms of transdermal drug absorption","authors":"Weijia Liu ,&nbsp;Mengjun Pan ,&nbsp;Shuo Pan ,&nbsp;Wanqing Dai ,&nbsp;Zhengguang Li ,&nbsp;Xiaoqin Chu","doi":"10.1016/j.jddst.2026.108055","DOIUrl":"10.1016/j.jddst.2026.108055","url":null,"abstract":"<div><div>The development of transdermal drug delivery systems (TDDS) relies on a thorough understanding of the mechanisms of drug permeation across the skin. Therefore, the application of various characterization techniques is very crucial, as it provides key information to reveal the interactions between drugs/formulations and skin. This review summarizes the selection of skin samples and experimental methods in current transdermal mechanism research, with a focus on the principles and applications of spectroscopy, thermal analysis, nuclear magnetic resonance, microscopy techniques, and other approaches such as activation energy, molecular simulation, mass spectrometry imaging, and optical coherence tomography. Drug prescriptions can be optimized to enhance bioavailability and therapeutic efficacy based on studies of the transdermal process. With the continuous emergence of new technologies, research on percutaneous absorption mechanisms will become more in-depth and precise, which will help improve the overall performance of TDDS and provide methodological support for the optimal design. Importantly, the integration of these advanced characterization techniques has been shown to significantly enhance our ability to predict and enhance drug permeation across the skin, leading to more effective TDDS formulations.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108055"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solid dispersions enhanced nystatin solubility without significant improvement in permeability: Potential application in localized therapies","authors":"Michelle Maria Gonçalves Barão de Aguiar ,&nbsp;Gina Polo ,&nbsp;Maíra Bueno Ariede ,&nbsp;Renata Miliani Martinez ,&nbsp;Fábia Rafaella Silva Alves ,&nbsp;Fernanda Isadora Boni ,&nbsp;André Rolim Baby ,&nbsp;Cristina Helena dos Reis Serra","doi":"10.1016/j.jddst.2026.108072","DOIUrl":"10.1016/j.jddst.2026.108072","url":null,"abstract":"<div><div>This study aimed to develop solid dispersions of nystatin using different carriers to enhance its solubility, impart mucoadhesive properties, and reduce permeability, aiming at local action in the buccal cavity. 1, 2 and 3 generation of NYS SD were developed, employing lactose, hydroxypropylmethylcellulose (HPMC), poloxamer 407 (P407) and poloxamer 188 (P188) as carriers. NYS SD were characterized by differential scanning calorimetry and thermogravimetry/derivative thermogravimetry. Further characterization was conducted with NYS SD that showed a specific thermal behavior suggesting the formation of a new system by solubility, power X-ray diffraction, Fourier transform infrared spectroscopy, and parallel artificial membrane permeability assay. The results demonstrated the feasibility of developing a 3 NYS SD system with enhanced solubility compared to raw NYS in water (4.484 mg/mL); at pH 5.5 (4.249 mg/mL) and pH 7.0 (4.293 mg/mL), making it more readily available in saliva and, consequently, within the oral cavity. Moreover, the <em>in vitro</em> permeation test did not show a significant increase in permeation, reinforcing the potential of the formulation for local action. In conclusion, NYS SDs were developed using a low-cost, reproducible rotary evaporation method and hydrophilic carriers, with F8—based on poloxamer 188—showing the most promising results. F8 exhibited a fourfold increase in aqueous solubility without altering mucosal permeability, addressing NYS's poor solubility, which may compromise its therapeutic efficacy. As a safe antifungal, NYS is a strong candidate for formulation strategies that enhance solubility. These findings support the continued investigation of F8 as a topical treatment for oral candidiasis.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108072"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic potentiation of anti-PD-L1 therapy via Glut1-targeted berberine liposomes functionalized with Rg3 in triple-negative breast cancer","authors":"Lujia Zhu ,&nbsp;Xiaokai Chi ,&nbsp;Jingyi Huang ,&nbsp;Yuhuan Kong ,&nbsp;Qiushuang Li ,&nbsp;Yang Xiong","doi":"10.1016/j.jddst.2026.108104","DOIUrl":"10.1016/j.jddst.2026.108104","url":null,"abstract":"<div><div>Immune activation through PD-L1 monoclonal antibodies (aPD-L1) represents a promising therapeutic strategy for triple-negative breast cancer (TNBC). However, the immunosuppressive tumor microenvironment (TME) of TNBC, characterized by an abundance of cancer-associated adipocytes (CAAs) that release lipids and promote lipid droplet (LD) accumulation in tumor cells, compromises the efficacy of aPD-L1 monotherapy. Berberine (BBR), a natural compound derived from <em>Coptis chinensis</em>, exhibits potent lipid-lowering and anti-tumor effects, yet its clinical application is limited by poor solubility, low bioavailability, and lack of tumor-specific targeting. To overcome these limitations, we developed a novel liposomal delivery system functionalized with ginsenoside Rg3 (Rg3) to encapsulate BBR (BR-Lip). Rg3 serves as a targeting ligand for glucose transporter 1 (GLUT1), which is highly expressed on TNBC cells. <em>In vitro</em> studies demonstrated that BR-Lip specifically binds to GLUT1, enhancing cellular uptake and drug delivery into tumor cells. <em>In vivo</em>, BR-Lip exhibited significant tumor-specific accumulation and retention for over 24 h post-administration. When combined with aPD-L1, BR-Lip synergistically inhibited tumor growth in 4T1-bearing mice, and the tumor inhibition rate was 73.08 ± 0.67%. Moreover, the combination therapy effectively remodeled the immunosuppressive TME, promoting the infiltration of cytotoxic T lymphocytes and dendritic cells, and achieving integrated effects of tumor suppression and immune activation. These findings highlight BR-Lip as a promising targeted strategy to potentiate aPD-L1 immunotherapy.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108104"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving roles of drug delivery systems for non-invasive treatment of neovascular age-related macular degeneration: advances and challenges","authors":"Nunnarpas Yongvongsoontorn,&nbsp;Joo Eun Chung,&nbsp;Motoichi Kurisawa","doi":"10.1016/j.jddst.2026.108088","DOIUrl":"10.1016/j.jddst.2026.108088","url":null,"abstract":"<div><div>Neovascular age-related macular degeneration (nAMD) is a leading cause of vision impairment in the elderly, characterized by pathological choroidal and retinal neovascularization that can result in irreversible vision loss if untreated. Current standard therapies rely on repeated intravitreal (IVT) injections of anti-vascular endothelial growth factor (VEGF) agents, which impose substantial burdens due to invasiveness, cumulative ocular risks, high costs, and poor long-term patient adherence. To address these limitations, alternative therapeutic strategies are under active investigation, including the development of novel drugs and drug delivery systems (DDSs) aimed at sustaining therapeutic efficacy and reducing injection frequency. Non-invasive delivery routes such as topical or oral administration are also being explored; however, conventional formulations delivered <em>via</em> these routes have repeatedly failed in clinical settings owing to inadequate bioavailability, rapid clearance, and limited capacity to overcome the complex ocular barriers of the posterior segment. These challenges are particularly pronounced for protein-based therapeutics, which remain the only approved drug class for nAMD and are intrinsically difficult to transport across ocular tissues. In this context, advanced DDSs play a critical role in enhancing ocular penetration and enabling targeted delivery to posterior choroidal and retinal tissues following non-invasive administration. In parallel, naturally derived compounds with anti-angiogenic activity are gaining attention for their favorable safety profiles and compatibility with emerging DDS platforms. This review highlights recent advances in nAMD treatment strategies focused on overcoming the limitations of invasive and conventional non-invasive approaches, with particular emphasis on DDS-driven solutions for effective and patient-friendly ocular therapies.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108088"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracellular delivery of anti-dengue envelope monoclonal antibodies via PEG-PLGA nanoparticles suppresses viral replication and attenuates hepatocyte apoptosis","authors":"Nutthanicha Intrarakasem ,&nbsp;Sorawee Kaewkarn ,&nbsp;Phitchapha Proykhunthod ,&nbsp;Adisak Songjaeng ,&nbsp;Panisadee Avirutnun ,&nbsp;Tanapan Prommool ,&nbsp;Chunya Puttikhunt ,&nbsp;Anupong Makeudom ,&nbsp;Atthapan Morchang ,&nbsp;Xiaohe Tian ,&nbsp;Giuseppe Battaglia ,&nbsp;Nisa Patikarnmonthon ,&nbsp;Romchat Kraivong","doi":"10.1016/j.jddst.2026.108086","DOIUrl":"10.1016/j.jddst.2026.108086","url":null,"abstract":"<div><div>Dengue virus (DENV) infection remains a major global health threat, with no specific antiviral treatment currently approved. Monoclonal antibody (mAb) therapy represents a promising strategy for viral inhibition; however, conventional antibodies are largely restricted to extracellular compartments and lack access to intracellular viral replication sites. In this study, we encapsulated a cross-reactive mAb targeting the DENV envelope protein (m513) into poly(ethylene glycol)-<em>block</em>-poly(lactide-<em>co</em>-glycolide) (PEG-PLGA) nanoparticles to facilitate intracellular delivery. When applied to immortalized hepatocyte-like cells (imHCs), the formulation demonstrated efficient cellular uptake, low cytotoxicity, and significantly reduced intracellular viral RNA and protein levels. The resulting formulation consisted of mAb-loaded PEG-PLGA nanoparticles (∼100 nm in diameter) with spherical morphology and an encapsulation efficiency of approximately 50%. Furthermore, nanoparticle treatment significantly reduced hepatocyte apoptosis in infected cells. Collectively, these findings demonstrate that nanoparticle-mediated intracellular antibody delivery can overcome a key limitation of conventional antibody therapy and represents a mechanistically distinct antiviral strategy for DENV and other intracellular viral infections.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108086"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal iron oxide nanoparticles for breast cancer theranostics and clinical translation: From bench to bedside","authors":"Zahid Hussain ,&nbsp;Rusel Mohammed Dhaidan ,&nbsp;Ahmad Alshammari ,&nbsp;Farida Ahmed Fikry ,&nbsp;Hnin Ei Thu","doi":"10.1016/j.jddst.2026.108111","DOIUrl":"10.1016/j.jddst.2026.108111","url":null,"abstract":"<div><div>Breast cancer remains the most prevalent malignancy among women and a leading cause of cancer-related mortality, underscoring the need for innovative strategies beyond conventional diagnostics and therapies. Iron oxide nanoparticles (IONPs) have emerged as versatile nanoplatforms owing to their superparamagnetic behavior, biocompatibility, and highly tunable physicochemical properties, including core size, crystallinity, surface chemistry, and multifunctional coatings. This review critically examines recent advances in IONP-based breast cancer theranostics, with particular emphasis on drug delivery, magnetic hyperthermia, photothermal therapy, and integrated platforms that combine imaging, targeting, and combinatorial treatment modalities. Rationally engineered IONPs enable enhanced tumor specificity through ligand-mediated uptake, pH- or enzyme-responsive drug release, and synergistic therapeutic efficacy when combined with chemotherapy, gene therapy, or immunotherapy. In parallel, their intrinsic magnetic properties support real-time treatment monitoring via MRI and complementary imaging techniques, reinforcing their value as true theranostic agents. Despite these advances, clinical translation remains constrained by safety considerations, long-term tissue retention, immunogenic surface coatings, and challenges associated with reproducible large-scale manufacturing under regulatory frameworks. Encouragingly, emerging clinical studies demonstrate the feasibility of MRI-guided hyperthermia and multifunctional IONP-based systems. Looking ahead, the integration of AI-guided design, immunoengineering, and biomarker-driven personalization is expected to address current limitations and accelerate clinical adoption. Collectively, IONPs represent a promising frontier in breast cancer management, offering materials-based solutions that bridge diagnostics and therapy within the paradigm of precision oncology.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108111"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amino acid polymer-based nano-carriers for targeted drug delivery in breast cancer therapy: Mechanisms, applications, and future perspectives: A literature review","authors":"Hamad S. Alyami ,&nbsp;Ghina Al-Atef","doi":"10.1016/j.jddst.2026.108120","DOIUrl":"10.1016/j.jddst.2026.108120","url":null,"abstract":"<div><div>Breast cancer remains a leading cause of women's mortality worldwide, despite considerable development in diagnosis and treatment strategies. Issues associated with conventional treatments, such as chemotherapy and radiotherapy, including systemic toxicity, side effects, and limited efficacy at advanced stages, have remained prominent challenges. Present advances in nanomedicine have shown that amino acid polymer-based nano-carriers are promising vehicles for targeted drug delivery in the treatment of breast cancer. These nano-carriers enhance biocompatibility, control and sustain drug release, exhibit better physicochemical stability, and show high selectivity for tumor tissues, thereby alleviating side effects in healthy tissues. This narrative review summarizes recent advancements in amino acid polymer-based nano-carriers, focusing on their design, drug-loading techniques, tumor microenvironment response, and ligand-mediated targeting methods. Also, it underscores current limitations, translation challenges, and research gaps, which need to be addressed to facilitate the successful implementation of clinical practices. Overall, these nano-carriers may improve breast cancer treatment by enhancing therapeutic precision and patient outcomes and contributing to the next generation of personalized nanomedicine.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108120"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative partitioning of model drugs across five pharmaceutical oils: Implications for passive loading in emulsions and oleosomes","authors":"Shengnan Zhao ,&nbsp;Jieyu Zuo ,&nbsp;Marlon C. Mallillin III ,&nbsp;Nadia Bou-Chacra ,&nbsp;Maryam Salami ,&nbsp;Tyson S. Le ,&nbsp;Neal M. Davies ,&nbsp;Raimar Löbenberg","doi":"10.1016/j.jddst.2026.108084","DOIUrl":"10.1016/j.jddst.2026.108084","url":null,"abstract":"<div><div>In biphasic delivery systems, particularly macro-emulsions and oleosomes, sufficient passive incorporation of drugs into the oil phase is a critical formulation attribute. Higher oil-phase loading not only ensures efficient drug encapsulation but also enables the development of robust, scalable, and clinically relevant lipid-based delivery platforms. Passive loading is governed by the interplay between drug properties and formulation physicochemical characteristics. From a molecular perspective, the ionization state of a drug at different pH values strongly influences oil–water partitioning, as unionized species can more effectively partition into the hydrophobic oil phase. At the same time, pharmaceutical oils differ in polarity, chain length, and glyceride backbone, making systematic evaluation of oil-dependent partitioning essential for rational formulation design. This study investigated the distribution behavior of three model compounds with distinct ionization characteristics, including melatonin (neutral), indomethacin (weak acid), and amitriptyline hydrochloride (weak base). Their partitioning was evaluated across five representative oil phases, including Labrafac PG (propylene glycol dicaprylocaprate), Labrafac Lipophile WL 1349 (medium-chain triglycerides), Peceol (glyceryl monooleate), Maisine CC (glyceryl monolinoleate), and canola oil (long-chain triglycerides), over the pH range of 3–10. All compounds exhibited pH-dependent partitioning consistent with their ionization profiles; however, notable differences emerged among oils. Melatonin displayed pronounced oil-dependent shifts, transitioning between hydrophilic and oleophilic behavior depending on the oil phase. A key finding was that partitioning trends, particularly for indomethacin and amitriptyline, were governed primarily by microstate transitions rather than octanol–water log D values, with ionization capable of reversing apparent hydrophilic and oleophilic tendencies. This mechanistic distinction underscores the importance of experimentally measured oil–water log D values, interpreted alongside microstate behavior, especially for compounds with multiple pKa values where charge-state distributions change rapidly with pH. From an oil perspective, short-chain glycerides (di- or triglycerides) exhibited comparable partitioning, whereas long-chain systems revealed clear differences between di- and triglyceride backbones. Among the three drugs, indomethacin displayed the greatest sensitivity to oil structure. These findings demonstrate that both drug ionization and oil composition determine passive loading efficiency in biphasic systems. Systematic partition profiling across multiple oils provides a rational, cost-effective approach to predict drug–oil compatibility and to support preformulation excipient selection in emulsions and oleosome-based lipid delivery systems.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108084"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on anti-breast cancer effect of paclitaxel palmitate and irinotecan hydrochloride co-encapsulated liposomes","authors":"Mengmeng Liu ,&nbsp;Qian Li ,&nbsp;Ning Fan ,&nbsp;Yanting Kuang ,&nbsp;Feng Yang ,&nbsp;Haolun Yang ,&nbsp;Xiaofeng Wang ,&nbsp;Dongfeng Yin","doi":"10.1016/j.jddst.2026.108059","DOIUrl":"10.1016/j.jddst.2026.108059","url":null,"abstract":"<div><div>Paclitaxel combined with irinotecan hydrochloride is used clinically, but it will face some other challenges when used in combination. For example: after the combination of drugs into the body, it is difficult to maintain the original synergistic effect, affecting the actual efficacy; more times and frequency of administration; long infusion time; long treatment cycle and increased adverse reactions. To improve the shortcomings of paclitaxel preparation with poor properties and short half-life, paclitaxel palmitate was prepared into fat-soluble prodrug paclitaxel palmitate. Paclitaxel palmitate was encapsulated in phospholipid bilayer by solvent injection method, and irinotecan hydrochloride was encapsulated in the internal water phase of liposomes by pH gradient method, thus the compound liposome delivery system of paclitaxel palmitate and irinotecan hydrochloride was constructed (PTX-PA/IR-L). The cytotoxicity of PTX and IR to breast cancer cells (4T1) was investigated by CCK-8 method, and the synergistic ratio of PTX and IR was 2:1. 4T1 breast cancer model was successfully constructed. Studies have shown that PTX-PA/IR-L can exert synergistic anti-tumor effect. In addition, the delivery system also provides a new idea for the further development of compound nano-preparations.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"118 ","pages":"Article 108059"},"PeriodicalIF":4.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}